SCHEMBL5004589

SCHEMBL5004589

CCOc1ccc(-n2c(C)cc(C(C)=O)c2C)c(C)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.53
MAPT P10636 6/20 0.52
ALDH1A1 P00352 5/20 0.52
KMT2A Q03164 5/20 0.52
MEN1 O00255 4/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MITF O75030 2/20 0.52
HKDC1 Q2TB90 2/20 0.52
LMNA P02545 2/20 0.52
GAA P10253 1/20 0.47
RXFP1 Q9HBX9 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.40
PKM P14618 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
ACACB O00763 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5005526 0.86 NOTUM (0.50) NOTUMMAPTALDH1A1KMT2AMEN1
SCHEMBL5004534 0.82 MAPT (0.74) NOTUMMAPTALDH1A1KMT2AMEN1
SCHEMBL5005313 0.82 ALDH1A1 (0.65) NOTUMMAPTALDH1A1KMT2AMEN1
SCHEMBL5004517 0.77 ALDH1A1 (0.50) NOTUMMAPTALDH1A1KMT2AMEN1
SCHEMBL12299467 0.77 KDM4E (0.58) MAPTALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL5004537 0.73 ALDH1A1 (0.49) NOTUMMAPTALDH1A1KMT2AMEN1
SCHEMBL5001206 0.71 ALDH1A1 (0.47) MAPTALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL5001446 0.70 MAPK1 (0.73) NOTUMMAPTALDH1A1KMT2AMEN1
SCHEMBL5009875 0.70 ALDH1A1 (0.63) NOTUMMAPTALDH1A1KMT2AMEN1
SCHEMBL5001445 0.70 CACNA2D1 (0.64)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465730-B2 Treatment of neuropathic pain with 6H-pyrrolo[3,4-d]pyridazine compounds MERCK & CO. INC. (US) 2008-12-16 US disclosed
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds MERCK SHARP & DOHME CORP. 2006-07-13 US disclosed
EP-1539168-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO(3,4-D)PYRIDAZINE COMPOUNDS Merck & Co., Inc. (US) 2005-06-15 EP disclosed
WO-2004006836-A2 TREATMENT OF NEUROPATHIC PAIN WITH 6H-PYRROLO[3,4-D]PYRIDAZINE COMPOUNDS MERCK & CO., INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154929-A1 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds GRIN2C, CACNA1C, CACNG4 NOTUM 3922/4885MAPT 455/4885ALDH1A1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.